Status:
RECRUITING
Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma
Lead Sponsor:
West China Hospital
Conditions:
Sarcomatoid Carcinoma
Liver Cancer
Eligibility:
All Genders
18+ years
Brief Summary
In recent years, researchers have conducted extensive studies on adjuvant therapy following surgical resection of liver cancer, exploring its potential benefits and seeking effective treatment strateg...
Eligibility Criteria
Inclusion
- patients who underwent liver resection
- patients' postoperative paraffin pathology and immunohistochemistry results were reviewed to identify those diagnosed with PHSC
Exclusion
- patients who received other anti-tumor treatments before surgery, such as radiofrequency ablation (RFA), transarterial chemoembolization (TACE), radiation therapy (RT), and systemic therapy;
- patients diagnosed with other specific types of sarcomas;
- patients with concurrent other malignancies during the course of PHSC;
- patients who were lost to follow-up or lacked essential clinical data.
Key Trial Info
Start Date :
April 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 5 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06950814
Start Date
April 5 2025
End Date
May 5 2025
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital
Chengdu, Sichuan, China, 610041